Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib
Introduction The efficacy of olaparib for treatment‐related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment‐related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1‐year efficacy. Case presentation A 75‐year‐old man initially d...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Wiley
2024-03-01
|
| Rangatū: | IJU Case Reports |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1002/iju5.12679 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|